Unknown PHASE4 INTERVENTIONAL 4-arm NCT04135989

Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES (PARTHENOPE)

Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Intervention

Sponsor: AdvicePharma Group

Conditions Acute Coronary Syndrome Chronic Coronary Syndrome Coronary Artery Disease Myocardial Infarction

Interventions Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease. Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease. Personalized DAPT duration Standard DAPT duration

Updated 13 times since 2019 Last updated: Feb 22, 2024 Started: Jan 1, 2020 Primary completion: Oct 24, 2021 Completion: Oct 24, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Acute Coronary Syndrome and Chronic Coronary Syndrome and is currently ongoing. AdvicePharma Group leads this study, which shows 13 recorded versions since 2020 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

13 versions recorded

Mar 2026 — Present [monthly]

Unknown PHASE4

Status: Active Not Recruiting → Unknown
Sep 2025 — Mar 2026 [monthly]

Active Not Recruiting PHASE4
Sep 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE4
Mar 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE4

▶ Show 8 earlier versions

Sep 2022 — Mar 2024 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting
Apr 2022 — Sep 2022 [monthly]

Recruiting PHASE4
Jan 2021 — Apr 2022 [monthly]

Recruiting PHASE4
Aug 2020 — Jan 2021 [monthly]

Recruiting PHASE4
May 2020 — Aug 2020 [monthly]

Recruiting PHASE4
Feb 2020 — May 2020 [monthly]

Recruiting PHASE4
Jan 2020 — Feb 2020 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Nov 2019 — Jan 2020 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AdvicePharma Group
Federico II University

Data source: Federico II University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Acerra, Italy , Avellino, Italy , Aversa, Italy , Caserta, Italy , Eboli, Italy , Giugliano in Campania, Italy , Naples, Italy , Napoli, Italy , Nola, Italy , Pozzuoli, Italy and 1 more location